This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: November 14, 2006
Last updated: November 6, 2015
Last verified: November 2015
The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of each dose will also be studied.

Condition Intervention Phase
Psoriasis Drug: BMS-582949 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • The primary endpoint is the proportion of subjects achieving an IGA score of clear or almost clear at Week 12 [ Time Frame: at Week 12 ]

Secondary Outcome Measures:
  • Proportion of subjects achieving a PASI-50 [ Time Frame: at Week 12 ]
  • Proportion of subjects achieving a PASI-75 [ Time Frame: at Week 12 ]
  • Proportion of subjects achieving a PASI-90 [ Time Frame: at Week 12 ]

Enrollment: 99
Study Start Date: August 2007
Study Completion Date: April 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A1
10 mg
Drug: BMS-582949
Tablets, Oral, Once daily, 12 weeks
Active Comparator: A2
30 mg
Drug: BMS-582949
Tablets, Oral, Once daily, 12 weeks
Active Comparator: A3
100 mg
Drug: BMS-582949
Tablets, Oral, Once daily, 12 weeks
Placebo Comparator: P1
10 or 100 mg
Drug: Placebo
Tablets, Oral, Once daily, 12 weeks


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females (not nursing or not pregnant)
  • 18-75 years of age
  • Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
  • Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00399906

Australia, New South Wales
Local Institution
Kogarah, New South Wales, Australia, 2217
Australia, Queensland
Local Institution
Greenslopes, Queensland, Australia, 4120
Australia, South Australia
Local Institution
North Adelaide, South Australia, Australia, 5006
Australia, Victoria
Local Institution
Carlton, Victoria, Australia, 3053
Local Institution
Malvern, Victoria, Australia, 3144
Canada, Alberta
Local Institution
Calgary, Alberta, Canada, T3A 2N1
Local Institution
Edmonton, Alberta, Canada, T5K 1X3
Canada, British Columbia
Local Institution
Surrey, British Columbia, Canada, V3R 6A7
Canada, Manitoba
Local Institution
Winnipeg, Manitoba, Canada, R2C 0N2
Canada, Newfoundland and Labrador
Local Institution
St. John'S, Newfoundland and Labrador, Canada, A1B 3E1
Canada, Nova Scotia
Local Institution
Halifax, Nova Scotia, Canada, B3H 1Z4
Canada, Ontario
Local Institution
Oakville, Ontario, Canada, L6J 7W5
Local Institution
Toronto, Ontario, Canada, M9W 4L6
Local Institution
Waterloo, Ontario, Canada, N2J 1C4
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H3H 1V4
Local Institution
St-Leonard, Quebec, Canada, H1S 3A9
Local Institution
Quebec, Canada, G1V 4X7
Local Institution
Mexico, Aguascalientes, Mexico, 20127
Local Institution
Df, Distrito Federal, Mexico, 06780
Local Institution
Zapopan, Jalisco, Mexico, 45190
Local Institution
Monterrey, Nuevo Leon, Mexico, 64060
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT00399906     History of Changes
Other Study ID Numbers: IM119-013
Study First Received: November 14, 2006
Last Updated: November 6, 2015

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases processed this record on September 21, 2017